In early trials, patients with melanomas harboring activating BRAF V600E mutations show high levels of response to BRAF inhibitor (BRAFi) treatment, which makes it a promising therapeutic strategy [5], [6], [7]. This evidence concerns the gene BRAF and melanoma.